X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs BIOCON LTD - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH BIOCON LTD STERLING BIOTECH/
BIOCON LTD
 
P/E (TTM) x -1.6 80.7 - View Chart
P/BV x 0.1 7.6 0.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 STERLING BIOTECH   BIOCON LTD
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
BIOCON LTD
Mar-17
STERLING BIOTECH/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs111,162 0.9%   
Low Rs3483 0.7%   
Sales per share (Unadj.) Rs26.8194.6 13.8%  
Earnings per share (Unadj.) Rs-15.034.4 -43.5%  
Cash flow per share (Unadj.) Rs-5.548.3 -11.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs54.9241.9 22.7%  
Shares outstanding (eoy) m267.87200.00 133.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.2 6.1%   
Avg P/E ratio x-0.523.9 -1.9%  
P/CF ratio (eoy) x-1.317.0 -7.5%  
Price / Book Value ratio x0.13.4 3.7%  
Dividend payout %02.9 0.0%   
Avg Mkt Cap Rs m1,862164,440 1.1%   
No. of employees `0001.49.2 14.7%   
Total wages/salary Rs m5477,470 7.3%   
Avg. sales/employee Rs Th5,303.34,213.9 125.9%   
Avg. wages/employee Rs Th403.8809.0 49.9%   
Avg. net profit/employee Rs Th-2,959.0745.2 -397.1%   
INCOME DATA
Net Sales Rs m7,18138,911 18.5%  
Other income Rs m431,571 2.7%   
Total revenues Rs m7,22340,482 17.8%   
Gross profit Rs m9479,795 9.7%  
Depreciation Rs m2,5432,772 91.7%   
Interest Rs m4,377260 1,683.5%   
Profit before tax Rs m-5,9318,334 -71.2%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,616 -119.1%   
Profit after tax Rs m-4,0076,881 -58.2%  
Gross profit margin %13.225.2 52.4%  
Effective tax rate %32.419.4 167.3%   
Net profit margin %-55.817.7 -315.5%  
BALANCE SHEET DATA
Current assets Rs m14,33540,477 35.4%   
Current liabilities Rs m49,80916,783 296.8%   
Net working cap to sales %-494.060.9 -811.3%  
Current ratio x0.32.4 11.9%  
Inventory Days Days40360 676.8%  
Debtors Days Days17183 206.0%  
Net fixed assets Rs m55,43245,073 123.0%   
Share capital Rs m2681,000 26.8%   
"Free" reserves Rs m13,93547,377 29.4%   
Net worth Rs m14,70148,377 30.4%   
Long term debt Rs m9,47821,082 45.0%   
Total assets Rs m73,98893,942 78.8%  
Interest coverage x-0.433.1 -1.1%   
Debt to equity ratio x0.60.4 147.9%  
Sales to assets ratio x0.10.4 23.4%   
Return on assets %0.57.6 6.6%  
Return on equity %-27.314.2 -191.6%  
Return on capital %-6.412.6 -51.0%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86012,988 14.3%   
Fx outflow Rs m257,899 0.3%   
Net fx Rs m1,8355,089 36.1%   
CASH FLOW
From Operations Rs m1,7196,400 26.9%  
From Investments Rs m-3,148-4,985 63.2%  
From Financial Activity Rs m1,426-1,775 -80.3%  
Net Cashflow Rs m-3-473 0.7%  

Share Holding

Indian Promoters % 33.9 40.4 83.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.0 8.4 -  
FIIs % 9.9 10.7 92.5%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 19.9 197.5%  
Shareholders   21,482 109,995 19.5%  
Pledged promoter(s) holding % 55.9 0.0 139,850.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Feb 22, 2018 01:05 PM

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - DR. DATSONS LABS COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS